Table 4 Clinical, EEG and laboratory variables associated with in hospital mortality
In hospital mortality | ||||||
|---|---|---|---|---|---|---|
Non-survivors (n = 28) | Survivors (n = 64) | Univariate | Multivariate analysis | |||
p value | p value | OR | CI 95% | |||
Age (> 65y) | 18 (64%) | 26 (41%) | 0.037 | – | ||
Female | 10 (36%) | 20 (31%) | 0.67 | – | ||
APACHE II | 27 [21–32] | 21 [20–26] | 0.008 | 0.059 | 1.05 | [0.99–1.11] |
non-neuro APACHE II | 19 [15–24] | 17 [10–23] | 0.233 | – | ||
APACHE II (> 23) | 17 (61%) | 24 (38%) | 0.039 | – | ||
CAM-ICU+ | 10/19 (53%) | 19/51 (37%) | 0.25 | – | ||
CRS-R | 3 [1–14] | 22 [7–23] | 0.001 | – | ||
GCS | 10 [5–15] | 14 [8–15] | 0.004 | – | ||
Sedation | 13 (46%) | 17 (27%) | 0.061 | – | ||
Propofol dose (mg/kg/day) | 24.2 [15–35.5] | 18 [4–37] | 0.36 | – | ||
Propofol duration (day) | 3 [2–6] | 1 [1–3] | 0.009 | – | ||
Mdz dose (mg/kg/day) | 0.1 [0.1–0.3] | 0.6 [0.6–0.9] | 0.03 | – | ||
Mdz duration (day) | 1.5 [1–2.75] | 2 [2–3] | 0.37 | – | ||
Dxd dose (µg/kg/day) | 3.4 [na] | 7.9 [7.5–16.7] | 0.5 | – | ||
Dxd duration (day) | 4 [na] | 2 [1.5–2] | 0.34 | – | ||
Vasoactive drugs | 24 (86%) | 52 (81%) | 0.6 | – | ||
Mechanical ventilation | 22 (79%) | 42 (66%) | 0.214 | – | ||
SAE | 25 (89%) | 15 (23%) | 0.013 | – | ||
cEEG rhythmic and periodic patterns | ||||||
RDA | 17 (61%) | 31 (48%) | 0.28 | – | ||
PDs | 12 (43%) | 11 (17%) | 0.009 | 0.038 | 2.94 | [1.07–8.18] |
PDs burden | [0–60]% | [0–30]% | 0.014 | – | ||
cEEG background | ||||||
Reactivity | 19 (68%) | 55 (86%) | 0.044 | – | ||
Sleep | 13 (46%) | 42 (66%) | 0.08 | – | ||
PDR | 23 (82%) | 59 (92%) | 0.15 | – | ||
High grade mSynek scale | 17 (61%) | 16 (25%) | 0.001 | – | ||
SB/suppressed | 2 (7%) | 1 (1%) | 0.22 | – | ||
Discontinuous/Low voltage | 6 (21%) | 5 (8%) | 0.06 | – | ||